It's melanoma.
Now what?
Navigate your melanoma journey confidently with DecisionDx-Melanoma.
Navigate your melanoma journey confidently with DecisionDx-Melanoma.
A melanoma diagnosis can feel overwhelming, and you may have questions about what comes next for your care. That’s where DecisionDx-Melanoma comes in: a genomic test that gives you a clearer picture of your individual risk of your melanoma spreading or coming back. This insight can help you and your clinician build a risk-aligned care plan personalized to you.
Intended for stage I–III cutaneous melanoma, DecisionDx-Melanoma analyzes a small sample from your original biopsy to evaluate your tumor’s unique biology, giving you additional information to help you move forward with greater confidence in your melanoma journey.
Represents the only melanoma genomic test shown to be associated with improved patient survival1.
Uses your tumor biology to provide personalized insights that help guide more precise care.
Offers coverage through Medicare and many private insurers, with a market-leading financial assistance program.
The DecisionDx-Melanoma test provides personalized information about your individual risk of your melanoma coming back or spreading, as well as the likelihood of melanoma being found in a nearby lymph node.
Understanding your individualized risk can help you and your clinician make more informed decisions about your care, including whether a sentinel lymph node biopsy may be appropriate, how often you should be seen for follow-up, whether a referral to another specialist may be appropriate, and other melanoma management decisions.
Not all melanoma genomic tests provide the same information. That’s why it’s important to ask your healthcare provider about DecisionDx-Melanoma by name.
DecisionDx-Melanoma provides a comprehensive, clinically validated, personalized risk assessment based on your tumor’s unique biology. It provides information about your individual risk of your melanoma coming back or spreading, as well as your likelihood of sentinel lymph node positivity. These insights can help inform important decisions throughout your melanoma care journey.
As the leader in prognostic melanoma genomic testing, DecisionDx-Melanoma is the only melanoma genomic test shown to be associated with improved patient survival. With 240,000+ test reports delivered, 13,000+ ordering clinicians, and 50+ peer-reviewed publications, DecisionDx-Melanoma is backed by extensive clinical evidence and experience to support informed melanoma care.
Explore the 50+ peer-reviewed publications and scientific evidence supporting DecisionDx-Melanoma and its use in melanoma care.
Wherever you are in your melanoma journey, you deserve clarity. Ask your provider about DecisionDx-Melanoma and take the next step toward informed, confident care.